Juvenile Idiopathic Arthritis: Diagnosis and Treatment

Rheumatology and Therapy

Volumn 3, Issue 2, 2016, Pages 187-207

  Giancane, Gabriella ^a,b   Consolaro, Alessandro ^a,b   Lanni, Stefano ^a   Davì, Sergio ^a   Schiappapietra, Benedetta ^a,b   Ravelli, Angelo ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Biologics; Biomarkers; Drug safety; Imaging; Juvenile idiopathic arthritis; Outcome measures

Indexed keywords

EID: 85016431132     PISSN: 21986576     EISSN: 21986584     Source Type: Journal    
DOI: 10.1007/s40744-016-0040-4     Document Type: Review

References (160)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–78. DOI: 10.1016/S0140-6736(07)60363-8
2. Petty RE, Cassidy JT. Textbook of pediatric rheumatology. Philadelphia: Saunders Elsevier; 2011.
3. Szer I, Kimura Y, Malleson P, Southwood T. Arthritis in children and adolescents. Oxford: Oxford University Press; 2006.
4. Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan. Acta Paediatr Jpn. 1997;39:245–9. DOI: 10.1111/j.1442-200X.1997.tb03593.x
5. Consolaro A, Ruperto N, Filocamo G, et al. Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: introduction of the EPOCA study. Pediatr Rheumatol Online J. 2012;10:39. DOI: 10.1186/1546-0096-10-39
6. Consolaro A, Ravelli A. Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - key to understanding etiology and genetic factors? J Rheumatol. 2016;43:683–5. DOI: 10.3899/jrheum.160173
7. Petty RE, Southwood TR, Manners P, et al. International League of Associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.
8. Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol. 1995;22:1566–9.
9. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25:1991–4.
10. Ramsey SE, Bolaria RK, Cabral DA, Malleson PN, Petty RE. Comparison of criteria for the classification of childhood arthritis. J Rheumatol. 2000;27:1283–6.
11. Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol. 2000;27:1069–72.
12. Fantini F. Classification of chronic arthritides of childhood (juvenile idiopathic arthritis): criticisms and suggestions to improve the efficacy of the Santiago-Durban criteria. J Rheumatol. 2001;28:456–9.
13. Krumrey-Langkammerer M, Häfner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol. 2001;28:2544–7.
14. Berntson L, Fasth A, Andersson-Gäre B, et al. Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol. 2001;28:2737–43.
15. Berntson L, Fasth A, Andersson-Gäre B, et al. The influence of heredity for psoriasis on the ILAR classification of juvenile idiopathic arthritis. J Rheumatol. 2002;29:2454–8.
16. Burgos-Vargas R, Rudwaleit M, Sieper J. The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol. 2002;29:869–74.
17. Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol. 2003;30:1900–3.
18. Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52:826–32. DOI: 10.1002/art.20945
19. Ravelli A, Varnier GC, Oliveira S, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:267–75. DOI: 10.1002/art.30076
20. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71:1437–9. DOI: 10.1136/annrheumdis-2012-201388
21. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12:56–9. DOI: 10.1016/j.autrev.2012.07.022
22. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604. DOI: 10.1016/j.jpeds.2004.12.016
23. Davì S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2871–80. DOI: 10.1002/art.38769
24. Davì S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8. DOI: 10.3899/jrheum.100996
25. Minoia F, Davì S, Bovis F, et al. Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol. 2014;12(Suppl 1). doi:10.1002/art.39332. DOI: 10.1002/art.39332
26. Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68:566–76. DOI: 10.1002/art.39332
27. Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Iniative. Ann Rheum Dis. 2016;75(3):481-9. DOI: 10.1136/annrheumdis-2015-208982
28. Ansell BM. Juvenile chronic arthritis. Scand J Rheumatol Suppl. 1987;66:47–50. DOI: 10.3109/03009748709102521
29. Al-Matar MJ, Petty RE, Tucker LB, Malleson PN, Schroeder ML, Cabral DA. The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46:2708–15. DOI: 10.1002/art.10544
30. Felici E, Novarini C, Magni-Manzoni S, et al. Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. J Rheumatol. 2005;32:1805–10.
31. Tsitsami E, Bozzola E, Magni-Manzoni S, et al. Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. Arthritis Rheum. 2003;49:488–93. DOI: 10.1002/art.11191
32. Ravelli A, Consolaro A, Schiappapietra B, Martini A. The conundrum of juvenile psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S40–3.
33. Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis. 1997;56:197–200. DOI: 10.1136/ard.56.3.197
34. Filocamo G, Davì S, Pistorio A, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37:1534–41. DOI: 10.3899/jrheum.091474
35. Filocamo G, Consolaro A, Ferrari C, Ravelli A. Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clin Exp Rheumatol. 2013;31:964–8.
36. Brunner HI, Ravelli A. Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2009;23:609–24. DOI: 10.1016/j.berh.2009.07.001
37. Brunner HI, Giannini EH. Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol. 2003;15:602–12. DOI: 10.1097/00002281-200309000-00014
38. Luca NJC, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2014;28:331–50. DOI: 10.1016/j.berh.2014.04.001
39. Feldman BM, Grundland B, McCullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000;27:226–33.
40. Pincus T, Yazici YSC. Quality control of a medical history: improving accuracy with patient participation, supported by a four-page version of the multidimensional health assessment questionnaire (MDHAQ). Rheum Dis Clin North Am. 2009;35:851–60. DOI: 10.1016/j.rdc.2009.10.014
41. Consolaro A, Giancane G, Schiappapietra B, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14:23. DOI: 10.1186/s12969-016-0085-5
42. Consolaro A, Negro G, Chiara Gallo M, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken). 2014;66:1703–9. DOI: 10.1002/acr.22393
43. Ravelli A. The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials. J Rheumatol. 2008;35:553–7.
44. Reed MH, Wilmot DM. The radiology of juvenile rheumatoid arthritis. A review of the English language literature. J Rheumatol Suppl. 1991;31:2–22.
45. Van Rossum MA, Zwinderman AH, Boers M, et al. Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method. Arthritis Rheum. 2003;48:507–15. DOI: 10.1002/art.10783
46. Magni-Manzoni S, Rossi F, Pistorio A, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:3509–17. DOI: 10.1002/art.11337
47. Rossi F, Di Dia F, Galipò O, et al. Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Care Res. 2006;55:717–23. DOI: 10.1002/art.22246
48. Ravelli A, Ioseliani M, Norambuena X, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:3087–95. DOI: 10.1002/art.22835
49. Doria AS, de Castro CC, Kiss MHB, et al. Inter- and intrareader variability in the interpretation of two radiographic classification systems for juvenile rheumatoid arthritis. Pediatr Radiol. 2003;33:673–81. DOI: 10.1007/s00247-003-0912-y
50. Mason T, Reed AM, Nelson AM, Thomas KB. Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. Ann Rheum Dis. 2005;64:491–3. DOI: 10.1136/ard.2003.017053
51. Van Rossum MAJ, Boers M, Zwinderman AH, et al. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. Arthritis Rheum. 2005;52:2865–72. DOI: 10.1002/art.21247
52. Cannizzaro E, Schroeder S, Müller LM, Kellenberger CJ, Saurenmann R. Temporomandibular joint involvement in children with juvenile idiopathic arthritis. J Rheumatol. 2011;38:510–5. DOI: 10.3899/jrheum.100325
53. Pedersen TK, Kuseler A, Gelineck J, Herlin T. A prospective study of magnetic resonance and radiographic imaging in relation to symptoms and clinical findings of the temporomandibular joint in children with juvenile idiopathic arthritis. J Rheumatol. 2008;35:1668–75.
54. Argyropoulou MI, Fanis SL, Xenakis T, Efremidis SC, Siamopoulou A. The role of MRI in the evaluation of hip joint disease in clinical subtypes of juvenile idiopathic arthritis. Br J Radiol. 2002;75:229–33. DOI: 10.1259/bjr.75.891.750229
55. Nistala K, Babar J, Johnson K, et al. Clinical assessment and core outcome variables are poor predictors of hip arthritis diagnosed by MRI in juvenile idiopathic arthritis. Rheumatology. 2007;46:699–702. DOI: 10.1093/rheumatology/kel401
56. Malattia C, Damasio MB, Basso C, et al. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49:178–85. DOI: 10.1093/rheumatology/kep343
57. McQueen FM. Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. Arthritis Res Ther. 2012;14:224. DOI: 10.1186/ar4035
58. Müller L, Avenarius D, Damasio B, et al. The paediatric wrist revisited: redefining MR findings in healthy children. Ann Rheum Dis. 2011;70:605–10. DOI: 10.1136/ard.2010.135244
59. Walther M, Harms H, Krenn V, Radke S, Kirschner S, Gohlke F. Synovial tissue of the hip at power Doppler US: correlation between vascularity and power Doppler US signal. Radiology. 2002;225:225–31. DOI: 10.1148/radiol.2251011272
60. Albrecht K, Müller-Ladner U, Strunk J. Quantification of the synovial perfusion in rheumatoid arthritis using Doppler ultrasonography. Clin Exp Rheumatol. 2006;25:630–8.
61. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761–73. DOI: 10.1002/art.22190
62. Spannow AH, Pfeiffer-Jensen M, Andersen NT, Herlin T, Stenbøg E. Ultrasonographic measurements of joint cartilage thickness in healthy children: age- and sex-related standard reference values. J Rheumatol. 2010;37:2595–601. DOI: 10.3899/jrheum.100101
63. Grassi W, Filippucci E, Farina A, Salaffi F, Cervini C. Ultrasonography in the evaluation of bone erosions. Ann Rheum Dis. 2001;60:98–103. DOI: 10.1136/ard.60.2.98
64. Lanni S, Wood M, Ravelli A, et al. Towards a role of ultrasound in children with juvenile idiopathic arthritis. Rheumatology (Oxford). 2013;52:413–20. DOI: 10.1093/rheumatology/kes287
65. Scott C, Meiorin S, Filocamo G, et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010;28:774–81.
66. Consolaro A, Varnier GC, Martini A, Ravelli A. Advances in biomarkers for paediatric rheumatic diseases. Nat Rev Rheumatol. 2014;11:1–11. DOI: 10.1038/nrrheum.2014.208
67. Hunter PJ, Nistala K, Jina N, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 2010;62:896–907. DOI: 10.1002/art.27284
68. Gibson DS, Finnegan S, Jordan G, et al. Stratification and monitoring of juvenile idiopathic arthritis patients by synovial proteome analysis. J Proteom Res. 2009;8:5601–9. DOI: 10.1021/pr900680w
69. Myles A, Aggarwal A. Expression of Toll-like receptors 2 and 4 is increased in peripheral blood and synovial fluid monocytes of patients with enthesitis-related arthritis subtype of juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50:481–8. DOI: 10.1093/rheumatology/keq362
70. Viswanath V, Myles A, Dayal R, Aggarwal A. Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis. J Rheumatol. 2011;38:2482–7. DOI: 10.3899/jrheum.110352
71. Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171–7. DOI: 10.3899/jrheum.130924
72. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50:3762–71. DOI: 10.1002/art.20631
73. Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974–80. DOI: 10.1136/annrheumdis-2011-200598
74. De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66:589–98. DOI: 10.1136/ard.2006.061853
75. Lotito APN, Campa A, Silva CAA, Kiss MHB, Mello SBV. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol. 2007;34:823–30.
76. Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford). 2013;52:1467–76. DOI: 10.1093/rheumatology/ket152
77. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266–73. DOI: 10.1001/jama.2010.375
78. Gerss J, Roth J, Holzinger D, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012;71:1991–7. DOI: 10.1136/annrheumdis-2012-201329
79. Vastert S, Prakken B. Update on research and clinical translation on specific clinical areas: from bench to bedside: how insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2014;28:229–46. DOI: 10.1016/j.berh.2014.05.002
80. Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol (Hoboken). 2014;66:1034–43. DOI: 10.1002/art.38296
81. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–8.
82. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–71. DOI: 10.1002/art.22416
83. Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis. Int J Rheum Dis. 2014;17:261–7. DOI: 10.1111/1756-185X.12196
84. Gorelik M, Fall N, Altaye M, et al. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2013;40:1191–9. DOI: 10.3899/jrheum.121131
85. Häfner R, Truckenbrodt H, Spamer M. Rehabilitation in children with juvenile chronic arthritis. Baillieres Clin Rheumatol. 1998;12:329–61. DOI: 10.1016/S0950-3579(98)80022-8
86. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2006;20:279–300. DOI: 10.1016/j.berh.2005.11.008
87. Toledo MMM, Martini G, Gigante C, Da Dalt L, Tregnaghi A, Zulian F. Is there a role for arthroscopic synovectomy in oligoarticular juvenile idiopathic arthritis? J Rheumatol. 2006;33:1868–72.
88. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465–82. DOI: 10.1002/acr.20460
89. Ruperto N, Nikishina I, Pachanov ED, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52:563–72. DOI: 10.1002/art.20860
90. Reiff A, Lovell DJ, Van Adelsberg J, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006;33:985–95.
91. Cleary AG, Murphy HD, Davidson JE. Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child. 2003;88:192–6. DOI: 10.1136/adc.88.3.192
92. Lanni S, Bertamino M, Consolaro A, et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology. 2011;50:1627–34. DOI: 10.1093/rheumatology/ker165
93. Papadopoulou C, Gonzalez MI, Nieto JC, et al. Delineating the role of multiple corticosteroid joint injections in the management of juvenile idiopathic arthritis in the biologic ERA. Arthritis Rheum. 2012;64:S503–S503.
94. Neidel J, Boehnke M, Küster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46:1620–8. DOI: 10.1002/art.10313
95. Tynjälä P, Honkanen V, Lahdenne P. Intra-articular steroids in radiologically confirmed tarsal and hip synovitis in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22:643–8.
96. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–78. DOI: 10.1016/S0140-6736(07)60363-8
97. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294:1671–84. DOI: 10.1001/jama.294.13.1671
98. Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol. 2000;27:1830–3.
99. Gutiérrez-Suárez R, Burgos-Vargas R. The use of methotrexate in children with rheumatic diseases. Clin Exp Rheumatol. 2010;28:S122–7.
100. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992;326:1043–9. DOI: 10.1056/NEJM199204163261602
101. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191–201. DOI: 10.1002/art.20288
102. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012;64:1349–56. DOI: 10.1002/acr.21697
103. Tuková J, Chládek J, Němcová D, Chládková J, Doležalová P. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009;27:1047–53.
104. Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004;31:179–82.
105. Ravelli A, Viola S, Ramenghi B, Beluffi G, Zonta LA, Martini A. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr. 1998;133:262–5. DOI: 10.1016/S0022-3476(98)70231-8
106. Harel L, Wagner-Weiner L, Poznanski AK, Spencer CH, Ekwo E, Magilavy DB. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36:1370–4. DOI: 10.1002/art.1780361007
107. Ortiz-Alvarez O, Morishita K, Avery G, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2004;31:2501–6.
108. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999;17:625–7.
109. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–66. DOI: 10.1056/NEJMoa041810
110. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–9. DOI: 10.1056/NEJM200003163421103
111. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–101. DOI: 10.1002/art.10885
112. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2794–804. DOI: 10.1002/art.24777
113. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638–44. DOI: 10.1136/ard.2003.014886
114. Prince FHM, Geerdink LM, Borsboom GJJM, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69:138–42. DOI: 10.1136/ard.2009.111260
115. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:3259–64. DOI: 10.1002/art.27682
116. Billiau AD, Loop M, Le PQ, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology. 2010;49:1550–8. DOI: 10.1093/rheumatology/keq123
117. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26:688–92.
118. Otten MH, Prince FHM, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306:2340–7. DOI: 10.1001/jama.2011.1671
119. Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40:192–200. DOI: 10.3899/jrheum.120842
120. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–106. DOI: 10.1002/art.22838
121. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20. DOI: 10.1056/NEJMoa0706290
122. Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66:2580–9. DOI: 10.1002/art.38741
123. Brunner H, Ruperto N, Tzaribachev N, et al. A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheumatol. 2014;66:S191–2. DOI: 10.1002/art.38569
124. Tynjala P, Vahasalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605–12. DOI: 10.1136/ard.2010.143347
125. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68:519–25. DOI: 10.1136/ard.2007.087593
126. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012–21. DOI: 10.1002/art.34343
127. Hugle B, Burgos-Vargas R, Inman RD, et al. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol. 2014;32:424–31.
128. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73:1114–22. DOI: 10.1136/annrheumdis-2012-203046
129. Kremer JM. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30:381–91, viii.
130. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383–91. DOI: 10.1016/S0140-6736(08)60998-8
131. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792–802. DOI: 10.1002/art.27431
132. Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2010;62:1542–51. DOI: 10.1002/acr.20283
133. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–7. DOI: 10.1136/annrheumdis-2014-205351
134. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994;93:2114–9. DOI: 10.1172/JCI117206
135. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol. 1998;25:203–7.
136. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479–86. DOI: 10.1084/jem.20050473
137. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071–5.
138. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–67. DOI: 10.1002/art.33342
139. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406. DOI: 10.1056/NEJMoa1205099
140. Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570–9. DOI: 10.1002/art.38699
141. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–55. DOI: 10.1002/art.30128
142. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol (Hoboken). 2014;66:1405–13. DOI: 10.1002/art.38615
143. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25. DOI: 10.1002/art.20944
144. Woo P, Wilkinson N, Prieur A-M, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged cli. Arthritis Res Ther. 2005;7:R1281–8. DOI: 10.1186/ar1826
145. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. DOI: 10.1016/S0140-6736(08)60454-7
146. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95. DOI: 10.1056/NEJMoa1112802
147. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163–72. DOI: 10.1007/s10067-011-1720-7
148. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology. 2011;50:189–95. DOI: 10.1093/rheumatology/keq308
149. Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology. 2011;50:230–6. DOI: 10.1093/rheumatology/keq361
150. Prince FHM, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–41. DOI: 10.1136/ard.2007.087411
151. Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22:252–8.
152. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517–24. DOI: 10.1002/art.27511
153. Lehman TJ. Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis? Arthritis Rheum. 2010;62:2183–4. DOI: 10.1002/art.27506
154. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:1263–71. DOI: 10.1002/art.34348
155. Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012;64:1357–64. DOI: 10.1002/acr.21709
156. Cron RQ, Beukelman T. Guilt by association—what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J. 2010;8:23. DOI: 10.1186/1546-0096-8-23
157. Ruperto N, Martini A. Juvenile idiopathic arthritis and malignancy. Rheumatology (Oxford). 2014;53(6):968–74. DOI: 10.1093/rheumatology/ket318
158. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–54. DOI: 10.1136/ard.2010.134254
159. Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4:387–97. DOI: 10.1177/1759720X12455960
160. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22:109–15. DOI: 10.3109/s10165-011-0481-0